We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
PTC Therapeutics announced that complete data from the Phase I single- and multiple-dose
studies and design of the planned Phase II studies for PTC124 were presented
at the 28th Annual European Cystic Fibrosis Conference in Crete, Greece.
Neurochem has completed recruitment of the 950 patients with mild-to-moderate
Alzheimer's disease (AD) for its North American Phase III clinical trial for
Alzhemed, the company's investigational product candidate for the treatment
of AD.
Genaera has initiated the first of two planned global Phase III clinical trials
(MSI-1256F-301) of its systemically administered anti-angiogenic drug, Evizon
(squalamine lactate), for the treatment of "wet" age-related macular
degeneration (AMD).
Halozyme Therapeutics, a biopharmaceutical company focused on the development
and commercialization of recombinant human enzymes, announced it has submitted
its investigational new drug (IND) application for Chemophase to the FDA.
AVANIR Pharmaceuticals announced that the company has submitted the final modules
of a "rolling" submission of the new drug application (NDA) for Neurodexan
investigational new drug, to the FDA as an electronic common technical document.
Genta announced that the company has initiated submission of a new drug
application (NDA) with the FDA seeking marketing approval of Genasense Injection,
its lead anticancer compound.
Arena Pharmaceuticals announced top-line results from its Phase I
clinical trials of APD125, Arena's orally administered, internally discovered
drug candidate for the treatment of insomnia.
Ariad Pharmaceuticals has announced initiation of enrollment of patients
with recurrent or persistent endometrial cancer in a global Phase II clinical
trial of its novel mTOR inhibitor, AP23573, as a single agent.
Organon, the human pharmaceutical business of Akzo Nobel, and Cypress
Bioscience have joined forces to attempt to develop and commercialize the first
novel pharmacological treatment for Obstructive Sleep Apnea (OSA).
AtheroGenics, a pharmaceutical company focused on the treatment of chronic inflammatory
diseases, announced that it has notified all clinical sites involved in its
worldwide pivotal Phase III clinical study, ARISE (Aggressive Reduction in Inflammation
Stops Events), that screening for patients in the trial will close on Friday,
July 8, 2005.